Amphastar Pharmaceuticals, Inc. P/E Ratio 2012–2025
Amphastar Pharmaceuticals, Inc. reported 13.19 of price-to-earnings ratio for fiscal 2025. That was 8.7% higher than fiscal 2024. Compared with fiscal 2020, the change was -98.0%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 13.19 | +8.7% |
| FY 2024 | 12.13 | -49.0% |
| FY 2023 | 23.79 | +47.7% |
| FY 2022 | 16.10 | -13.6% |
| FY 2021 | 18.63 | -97.2% |
| FY 2020 | 670.33 | +3305.5% |
| FY 2019 | 19.68 | — |
| FY 2018 | — | — |
| FY 2017 | 240.50 | +174.2% |
| FY 2016 | 87.71 | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
Source: Amphastar Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open AMPH 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Amphastar Pharmaceuticals, Inc. reported 13.19 of price-to-earnings ratio for fiscal 2025. That was 8.7% higher than fiscal 2024. Compared with fiscal 2020, the change was -98.0%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Amphastar Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmphastar Pharmaceuticals, Inc. — frequently asked questions
What is Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio?
Amphastar Pharmaceuticals, Inc. (AMPH) reported price-to-earnings ratio of 13.19 for fiscal year 2025, per its SEC filings.
How has Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2012 and 2025, AMPH's price-to-earnings ratio declined at roughly 13.6% per year (compound annual rate), from 87.71 to 13.19.
Where does this data come from?
Figures are computed from Amphastar Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More AMPH financial history
Full AMPH fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →